Neuropsychiatric Disorders Treatment Market
Description
The Global Neuropsychiatric Disorders Treatment Market is estimated to be valued at USD 76.21 Bn in 2025 and is expected to reach USD 101.64 Bn by 2032, growing at a compound annual growth rate (CAGR) of 4.2% from 2025 to 2032. The global neuropsychiatric disorders treatment market represents a critical segment within the broader healthcare landscape, encompassing therapeutic interventions for complex conditions that affect both neurological and psychiatric functions.
Neuropsychiatric disorders include a diverse range of conditions such as depression, anxiety, bipolar disorder, schizophrenia, attention deficit hyperactivity disorder (ADHD), autism spectrum disorders, and neurodegenerative diseases like Alzheimer's and Parkinson's disease. These conditions significantly impact patients' cognitive, emotional, and behavioral functioning, creating substantial healthcare burdens worldwide.
The treatment market encompasses various therapeutic modalities including pharmacological interventions, psychotherapy, neurostimulation techniques, and emerging innovative therapies such as digital therapeutics and precision medicine approaches. The increasing prevalence of neuropsychiatric disorders globally, driven by factors such as aging populations, lifestyle changes, increased stress levels, and improved diagnostic capabilities, has intensified the demand for effective treatment solutions.
Healthcare systems worldwide are recognizing the substantial economic and social impact of these conditions, leading to increased investment in research and development of novel therapeutic approaches. The market is characterized by continuous innovation, with pharmaceutical companies, biotechnology firms, and medical device manufacturers actively developing next-generation treatments that promise improved efficacy, reduced side effects, and personalized treatment protocols to address the complex and heterogeneous nature of neuropsychiatric disorders.
Market Dynamics
The global neuropsychiatric disorders treatment market is propelled by several key drivers that are fundamentally reshaping the therapeutic landscape. The primary driver is the escalating global prevalence of neuropsychiatric conditions, with the World Health Organization reporting that mental health disorders affect over 970 million people worldwide, while neurodegenerative diseases continue to rise with aging populations.
Increased awareness and reduced stigma surrounding mental health have led to higher diagnosis rates and treatment-seeking behavior, substantially expanding the patient pool. Technological advancements in drug discovery, including artificial intelligence-driven research, biomarker identification, and personalized medicine approaches, are accelerating the development of more targeted and effective therapies.
Government initiatives and increased healthcare spending on mental health services, particularly post-pandemic, have created favorable regulatory environments and funding opportunities. However, the market faces significant restraints including the high cost of drug development and lengthy approval processes, which can span 10-15 years and cost billions of dollars. Stringent regulatory requirements for neuropsychiatric medications, given their complex mechanisms and potential side effects, create additional barriers to market entry. The heterogeneous nature of these disorders makes treatment standardization challenging, while issues such as treatment resistance, medication adherence, and limited understanding of complex brain mechanisms continue to impede progress.
Despite these challenges, substantial opportunities exist in emerging markets with improving healthcare infrastructure and increasing mental health awareness. The integration of digital therapeutics, telemedicine, and AI-powered diagnostic tools presents new avenues for market expansion. Growing focus on early intervention, preventive care, and combination therapies offers potential for market growth, while the development of novel drug delivery systems and breakthrough therapies for treatment-resistant conditions represents significant commercial opportunities for innovative companies positioned to address these critical unmet medical needs.
Key Features of the Study
Neuropsychiatric disorders include a diverse range of conditions such as depression, anxiety, bipolar disorder, schizophrenia, attention deficit hyperactivity disorder (ADHD), autism spectrum disorders, and neurodegenerative diseases like Alzheimer's and Parkinson's disease. These conditions significantly impact patients' cognitive, emotional, and behavioral functioning, creating substantial healthcare burdens worldwide.
The treatment market encompasses various therapeutic modalities including pharmacological interventions, psychotherapy, neurostimulation techniques, and emerging innovative therapies such as digital therapeutics and precision medicine approaches. The increasing prevalence of neuropsychiatric disorders globally, driven by factors such as aging populations, lifestyle changes, increased stress levels, and improved diagnostic capabilities, has intensified the demand for effective treatment solutions.
Healthcare systems worldwide are recognizing the substantial economic and social impact of these conditions, leading to increased investment in research and development of novel therapeutic approaches. The market is characterized by continuous innovation, with pharmaceutical companies, biotechnology firms, and medical device manufacturers actively developing next-generation treatments that promise improved efficacy, reduced side effects, and personalized treatment protocols to address the complex and heterogeneous nature of neuropsychiatric disorders.
Market Dynamics
The global neuropsychiatric disorders treatment market is propelled by several key drivers that are fundamentally reshaping the therapeutic landscape. The primary driver is the escalating global prevalence of neuropsychiatric conditions, with the World Health Organization reporting that mental health disorders affect over 970 million people worldwide, while neurodegenerative diseases continue to rise with aging populations.
Increased awareness and reduced stigma surrounding mental health have led to higher diagnosis rates and treatment-seeking behavior, substantially expanding the patient pool. Technological advancements in drug discovery, including artificial intelligence-driven research, biomarker identification, and personalized medicine approaches, are accelerating the development of more targeted and effective therapies.
Government initiatives and increased healthcare spending on mental health services, particularly post-pandemic, have created favorable regulatory environments and funding opportunities. However, the market faces significant restraints including the high cost of drug development and lengthy approval processes, which can span 10-15 years and cost billions of dollars. Stringent regulatory requirements for neuropsychiatric medications, given their complex mechanisms and potential side effects, create additional barriers to market entry. The heterogeneous nature of these disorders makes treatment standardization challenging, while issues such as treatment resistance, medication adherence, and limited understanding of complex brain mechanisms continue to impede progress.
Despite these challenges, substantial opportunities exist in emerging markets with improving healthcare infrastructure and increasing mental health awareness. The integration of digital therapeutics, telemedicine, and AI-powered diagnostic tools presents new avenues for market expansion. Growing focus on early intervention, preventive care, and combination therapies offers potential for market growth, while the development of novel drug delivery systems and breakthrough therapies for treatment-resistant conditions represents significant commercial opportunities for innovative companies positioned to address these critical unmet medical needs.
Key Features of the Study
- This report provides in-depth analysis of the global neuropsychiatric disorders treatment market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025–2032), considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global neuropsychiatric disorders treatment market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Johnson and Johnson, Pfizer Inc, Roche Holding AG, Novartis AG, Eli Lilly and Company, Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Otsuka Holdings Co Ltd, H. Lundbeck A/S, AbbVie Inc (including Allergan), Biogen Inc, Teva Pharmaceutical Industries Ltd, and Janssen Pharmaceutical Companies
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global neuropsychiatric disorders treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global neuropsychiatric disorders treatment market
- Disorder Insights (Revenue, USD Bn, 2020 - 2032)
- Major Depressive Disorder
- Bipolar Disorder
- Anxiety Disorders
- Schizophrenia Spectrum Disorders
- Trauma- and Stressor-Related Disorders
- Obsessive-Compulsive and Related Disorders
- Attention-Deficit/Hyperactivity Disorder
- Autism Spectrum Disorder
- Substance Use Disorders
- Sleep-Wake Disorders
- Neurocognitive Disorders
- Movement Disorders with psychiatric symptom control
- Eating Disorders
- Personality Disorders
- Drug Class Insights (Revenue, USD Bn, 2020 - 2032)
- Antidepressants
- Antipsychotics
- Mood Stabilizers
- Anxiolytics and Sedative-Hypnotics
- ADHD Medications
- Cognitive Enhancers
- Substance Use Disorder Medications
- Movement and Impulse Control Agents
- Adjunctive Symptom-Control Agents
- Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
- Oral
- Parenteral
- Intranasal
- Transdermal
- Sublingual or Buccal
- Molecule Type Insights (Revenue, USD Bn, 2020 - 2032)
- Small molecules
- Biologics
- Combination drugs (fixed-dose combinations
- Formulation Type Insights (Revenue, USD Bn, 2020 - 2032)
- Immediate release
- Extended release or controlled release
- Long-acting depot formulations
- Orally disintegrating formulations
- Liquid oral formulations
- Prodrug formulations
- Patient Age Group Insights (Revenue, USD Bn, 2020 - 2032)
- Pediatric
- Adolescent
- Adult/Geriatric
- Care Setting Insights (Revenue, USD Bn, 2020 - 2032)
- Inpatient
- Outpatient
- Community-based Care
- Home-based Care
- Telehealth and Virtual Care
- Provider Type Insights (Revenue, USD Bn, 2020 - 2032)
- Psychiatrists
- Neurologists
- Primary Care Physicians
- Psychologists and Therapists
- Addiction Medicine Specialists
- Integrated Care Teams
- Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Payment Type Insights (Revenue, USD Bn, 2020 - 2032)
- Public
- Private
- Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Johnson and Johnson
- Pfizer Inc
- Roche Holding AG
- Novartis AG
- Eli Lilly and Company
- Bristol-Myers Squibb Company
- AstraZeneca PLC
- GlaxoSmithKline plc
- Takeda Pharmaceutical Company Limited
- Otsuka Holdings Co Ltd
- Lundbeck A/S
- AbbVie Inc (including Allergan)
- Biogen Inc
- Teva Pharmaceutical Industries Ltd
- Janssen Pharmaceutical Companies
Table of Contents
168 Pages
- 1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- 2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Neuropsychiatric Disorders Treatment Market, By Disorder
- Global Neuropsychiatric Disorders Treatment Market, By Drug Class
- Global Neuropsychiatric Disorders Treatment Market, By Route of Administration
- Global Neuropsychiatric Disorders Treatment Market, By Molecule Type
- Global Neuropsychiatric Disorders Treatment Market, By Formulation Type
- Global Neuropsychiatric Disorders Treatment Market, By Patient Age Group
- Global Neuropsychiatric Disorders Treatment Market, By Care Setting
- Global Neuropsychiatric Disorders Treatment Market, By Provider Type
- Global Neuropsychiatric Disorders Treatment Market, By Distribution Channel
- Global Neuropsychiatric Disorders Treatment Market, By Payment Type
- Global Neuropsychiatric Disorders Treatment Market, By Region
- 3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER’s Analysis
- Merger and Acquisition Scenario
- Industry Trends
- 4. Global Neuropsychiatric Disorders Treatment Market, By Disorder, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Major Depressive Disorder
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Bipolar Disorder
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Anxiety Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Schizophrenia Spectrum Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Trauma- and Stressor-Related Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Obsessive-Compulsive and Related Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Attention-Deficit/Hyperactivity Disorder
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Autism Spectrum Disorder
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Substance Use Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Sleep-Wake Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Neurocognitive Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Movement Disorders with psychiatric symptom control
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Eating Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Personality Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- 5. Global Neuropsychiatric Disorders Treatment Market, By Drug Class, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Antidepressants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Antipsychotics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Mood Stabilizers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Anxiolytics and Sedative-Hypnotics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- ADHD Medications
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Cognitive Enhancers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Substance Use Disorder Medications
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Movement and Impulse Control Agents
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Adjunctive Symptom-Control Agents
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- 6. Global Neuropsychiatric Disorders Treatment Market, By Route of Administration, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Intranasal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Transdermal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Sublingual or Buccal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- 7. Global Neuropsychiatric Disorders Treatment Market, By Molecule Type, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Small molecules
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Biologics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Combination drugs (fixed-dose combinations
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- 8. Global Neuropsychiatric Disorders Treatment Market, By Formulation Type, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Immediate release
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Extended release or controlled release
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Long-acting depot formulations
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Orally disintegrating formulations
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Liquid oral formulations
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Prodrug formulations
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- 9. Global Neuropsychiatric Disorders Treatment Market, By Patient Age Group, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Pediatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Adolescent
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Adult/Geriatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- 10. Global Neuropsychiatric Disorders Treatment Market, By Care Setting, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Inpatient
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Outpatient
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Community-based Care
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Home-based Care
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Telehealth and Virtual Care
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- 11. Global Neuropsychiatric Disorders Treatment Market, By Provider Type, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Psychiatrists
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Neurologists
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Primary Care Physicians
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Psychologists and Therapists
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Addiction Medicine Specialists
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Integrated Care Teams
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- 12. Global Neuropsychiatric Disorders Treatment Market, By Distribution Channel, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- 13. Global Neuropsychiatric Disorders Treatment Market, By Payment Type, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Public
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Private
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- 14. Global Neuropsychiatric Disorders Treatment Market, By Region, 2020 - 2032, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Disorder, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Molecule Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Formulation Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Patient Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Care Setting, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Provider Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Payment Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Disorder, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Molecule Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Formulation Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Patient Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Care Setting, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Provider Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Payment Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Disorder, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Molecule Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Formulation Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Patient Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Care Setting, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Provider Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Payment Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Disorder, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Molecule Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Formulation Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Patient Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Care Setting, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Provider Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Payment Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Disorder, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Molecule Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Formulation Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Patient Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Care Setting, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Provider Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Payment Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Disorder, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Molecule Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Formulation Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Patient Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Care Setting, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Provider Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Payment Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
- 15. Competitive Landscape
- Johnson and Johnson
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Roche Holding AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bristol-Myers Squibb Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AstraZeneca PLC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- GlaxoSmithKline plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Takeda Pharmaceutical Company Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Otsuka Holdings Co Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Lundbeck A/S
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AbbVie Inc (including Allergan)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Biogen Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Janssen Pharmaceutical Companies
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- 16. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
- 17. References and Research Methodology
- References
- Research Methodology
- About us
- *Browse 32 market data tables and 28 figures on ‘Neuropsychiatric Disorders Treatment Market' - Global forecast to 2032
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
